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Colorectal carcinoma is the third most prevalent cancer in the world. In the most advanced stages, the use of chemotherapy
induces a poor response and is usually accompanied by other tissue damage. Significant progress based on suicide gene therapy
has demonstrated that it may potentiate the classical cytotoxic effects in colorectal cancer. The inconvenience still rests with the
targeting and the specificity efficiency. The main target of gene therapy is to achieve an effective vehicle to hand over therapeutic
genes safely into specific cells. One possibility is the use of tumor-specific promoters overexpressed in cancers. They could induce
a specific expression of therapeutic genes in a given tumor, increasing their localized activity. Several promoters have been assayed
into direct suicide genes to cancer cells.This reviewdiscusses the current status of specific tumor-promoters and their great potential
in colorectal carcinoma treatment.
1. Background
Colorectal carcinoma (CRC) is the third most prevalent
cancer in the world [1]. Themain treatments, such as 5-fluor-
ouracil (5-FU) alone or combined (FOLFOX and FOLFIRI),
new angiogenesis inhibitors, and epidermal growth factor
receptor inhibitors, induce a poor response inmost advanced
stages and are usually accompanied by other tissue damage
[2]. Suicide gene therapy has been widely used in many
studies in vitro and in vivo, demonstrating that it may
potentiate the classical cytotoxic effects in some tumors [3],
including colon cancer [4, 5]. However, gene therapy applica-
tion in cancer patients has not yet successfully gained clinical
significance. The inconvenience still rests with targeting and
efficiency of the specificity.
For this purpose, it is necessary to express these genes
into specific tumor cells. The main target of gene therapy is
to achieve an effective vehicle to hand over therapeutic genes
safely into specific cells. One possibility is the use of tumor-
specific promoters, overexpressed in cancer cells. They could
induce a specific expression of therapeutic genes in a type of
tumor increasing their localized activity (Figure 1).
For instance, the TTS system (TTF1 gene under the
control of hTERT promoter and hSPA1 promoter) shows a
selective activity in lung cancer cells but not in other types of
cancer or normal cells [6]. Other promoters employed in gene
therapy are the 𝛼 fetoprotein (AFP) promoter (for hepatic
cancer) [7, 8] and the erb2 promoter (for breast cancer)
[9, 10]. It has been demonstrated that the hTERT promoter is
able to direct the expression of the PEA-15 gene, a tumor
suppressor gene and inhibitor of cell growth and invasion
[11–13], specifically to breast cancer cells, inducing growth
suppression and inhibition. This decrease is also observed in
the tumor growth of orthotopic animal models, as well as a
prolongation of survival time [14]. Similar results have been
found by Zhang et al. [15], who have proved the capacity of
the tumor-specific promoter hTERT to drive the expression
of the apoptin and E1A genes in prostate carcinoma cells and
in mouse models. Apoptin, a protein derived from chicken
anemia virus VP3 gene, is able to induce selective apoptosis
in human tumor and transformed cells but shows little or
no cytotoxic effect in many normal human cells [16, 17].
Several promoters such as carcinoembryonic antigen (CEA),
cyclooxygenase-2 (COX-2) [18], human telomerase reverse
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Figure 1: Schematic representation of a colon cancer specific promoter and the induction of therapeutic gene expression. High levels of
specific transcription factors in colon cancer cells are able to induce therapeutic gene expression. By contrast, no expression of these specific
transcription factors in normal colon cells avoids the transcription of the therapeutic gene.
transcriptase [19], andUrokinase-type plasminogen activator
receptor (uPAR) [20] have been assayed to direct suicide
genes into CRC cells.
In this review, we are going to show the current status of
specific tumor-promoters and their great potential in CRC
treatment.
2. Tumor-Promoters in Colorectal Carcinoma
2.1. CEA. Carcinoma embryonic antigen (CEA) is an oncofe-
tal tumor marker overexpressed in over 90% of colorectal
cancer cells but not in normal colon cells [21–23]. High
levels of serum CEA and high expressions of CEA mRNA
have been detected in patients in the last stages of human
colon carcinogenesis [24, 25]. CEA levels have been used
for predicting the prognosis and monitoring recurrence and
metastasis in patients with stage II CRC [26]. In fact, CEA
showed clinical and pathological significance as prognostic
markers in the diagnosis of colorectal cancer [26, 27], local
recurrence, and overall survival after resection [28]. This
elevated CEA promoter expression has also been shown
in cancer cell lines versus nontumor cell lines [29, 30].
In response to this tumor specificity, CEA promoter has
been studied to drive the expression of therapeutic genes
to CEA positive cancer cells [18]. Zhang et al. [30] studied
the efficiency of the double system cytosine deaminase (CD)
and thymidine kinase (TK) targeted by CEA promoter in
CEApositive human gastric cancer cell line (SGC7901) versus
a CEA negative human adenocarcinoma cell line (HeLa),
showing a greater growth inhibition in SGC7901 (89.8%)
than in HeLa line cell (2%). Similar findings were revealed
in the CEA positive human colon cancer cell line (LoVo).
After 5 days of 5-FC treatment, HeLa cells transfected with
CEA-CD were not sensitized by the cytotoxicity, whereas
transfected LoVo cells showed a cell growth inhibition of
72.7% [31]. In vivo studies demonstrated a similar effect in
LoVo xenografts mice treated with the CEA-CD system [31]
and in xenograft SGC7901 treatment with the double system
CEA-CD-TK (46% tumor growth inhibition rate (TGIR)
versus nontreated tumor control) [30]. Current study of
Rama et al. [32] reveled the ability of the CEA promoter to
direct𝐸 gene expression towards colon cancer cells, inducting
a high cell growth inhibition in comparison to normal human
colon cells (Figure 2). In addition, in vivo analyses of mice
bearing subcutaneous MC-38 colon cancer cells showed a
significant decrease in tumor volume and low level of Ki-67
in relation to untreated tumors.
2.2. Cox-2. Cyclooxygenase-2 (Cox-2) is an enzyme which
participates together with COX-1 in the oxidation of arachi-
donic acid to prostaglandin, an essential promoting factor
in carcinogenesis and development of tumors [33, 34]. Some
studies have demonstrated that uses of inhibitors against
Cox-2 suppress colon carcinogenesis [34, 35]. Cox-2 is
associated to CRC [36], exhibiting expression in 93% of
colon cancers and in 87% of rectal cancers [37], to polyps
with high-grade [38, 39], to a higher TNM (tumor, node,
metastasis) class, and to higher Dukes’ stage [40]. In a study
on 35 cases of CRC, 77% of them were Cox-2 positive and
43% showed location in the rectum and left side [41]. This
overexpression has been associated with the reduced survival
of CRC patients [42]. Furthermore, the recent study has















Figure 2: Antitumor effect of the 𝐸 gene under CEA promoter. The high transcriptional activity of the CEA promoter in colon cancer cells
leads to𝐸 gene expression which encodes a cytotoxic protein.The protein E targets mitochondria in colon cancer cells, disrupting their cristae
and inducing apoptosis by release of cytochrome c and activation of caspases 9 and 3.
than in rectal cancer (87%), associating this decrease of
Cox-2 expression to decreased disease-specific survival and
decreased disease-free survival in rectal cancer but not in
colon cancer, suggesting the Cox-2 expression as a predictive
clinical biomarker of rectal but not colon cancer [37].
This elevated Cox-2 promoter expression has also been
shown in cancer cell lines versus nontumor cancer cell
lines [43–45]. Wang et al. [45] analyzed the transcriptional
activity of Cox-2 promoter by the luciferase reporter gene
in colorectal cancer cell lines and normal human intestinal
epithelial cell lines.The results proved an increased luciferase
activity in all colorectal cancer lines (a median of 83% of
the three of them) relative to normal cells (12%). Based on
this specific-tumor activity, Cox-2 promoter has been used to
target different genes to specific colon cancer cells [43, 45].
The system Cox-2-TK conferred ganciclovir sensitivity to
LoVo tumor cells and 52.5 ± 1.2% inhibitory rates but did
not affect normal cells [45]. Another similar study has used
the Cox-2 promoter to drive the 15-hydroxyprostaglandin
dehydrogenase (15-PGDH), a gene suppressed in the majority
of cancers. 15-PGDH specific expression, underCox-2 control
promoter in colon cancer cells, inhibited growth and migra-
tion of colon cells [43]. In vivo studies demonstrated a similar
effect in LoVo xenografts treated with Cox-2-TK, showing
59.4% inhibitory rates versus nontreated LoVo xenografts
[45]. Thus, Kaliberova et al. [43] corroborated the effect of
the system Cox-2-15-PGDH in LS174T xenografts, disclosing
an inhibitory effect on tumor growth compared to nontreated
xenografts.
2.3. A33. A33 is a transmembrane glycoprotein member of
the immunoglobulin superfamily, present only in the small
intestine and colon [20, 46] and is associated with the process
of cell adhesion, cell trafficking, and intestinal immune
response [47, 48]. A33 overexpression is related to several
cancers such as primary andmetastatic colorectal carcinomas
(95%), diffuse gastric cancers (63%), intestinal-type gastric
cancers (83%), and pancreatic cancers (50%) but has been
undetected in normal epithelial tissue [49, 50]. However, the
expression level of A33 is not correlated to the disease stage
and the degree of histological differentiation [51].
Having established this specific expression of A33 in
gastrointestinal cancer, several immunotherapy assays have
manipulated different humanized A33 antibody fragments,
targeting them as specific carriers of other molecules (im-
munoconjugates) for antitumor treatment [52–54]. Recently,
Cafferata et al. [55] have used the A33 promoter in the
design of a conditionally replicative adenovirus to specifically
drive the essential early E1A gene into CRC cells. E1A is
an oncoprotein with several anticancer activities such as
decreasing tumorigenic potential, increasing inhibition of cell
growth and promoting apoptosis [56, 57]. They showed A33
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mRNA expression levels in different colorectal carcinoma cell
lines, but not in normal colonic cells, breast cancer cell lines,
hepatocellular carcinoma cell lines, fetal lung fibroblast cell
lines, melanoma cell lines, and embryonic kidney cells. This
was related to the activity of the A33 promoter, essentially
active only in human CRC cells whereas human mammary
and melanoma cells showed strongly reduced activity. Sub-
sequently, the adenovirus showed specific lytic activity in
human colorectal carcinoma cell lines and a slight activity
in hepatocellular carcinoma and melanoma cell lines. To
improve this therapeutic effect, the A33-E1A adenovirus was
combined with 5-FU administration, exhibiting an enhanced
lytic effect of 5-FU colon cancer cell lines compared with the
5-FU treatment alone. In vivo, the adenovirus was effective
in inhibiting tumor growth in 100% of LoVo xenografts;
treated mice survived significantly longer than the control
group. However, no evidence was observed in melanoma
xenografts. Also, liver metastasis was studied, displaying
absence of metastatic nodules (10/11 mice injected with A33-
E1A adenovirus) and strongly reduced metastatic areas (1/11).
Nonetheless, adding 5-FU in combination with the A33-E1A
adenovirus did not significantly improve the tumor growth
inhibitory effect observed with A33-E1A adenovirus alone.
2.4. TERT. Telomere/telomerase interplay has a prominent
role in the preservation of genetic chromosome stability
and its failure is involved in carcinogenesis [58]. Human
telomerase has two subunits: a template RNA component
(hTR) and a catalytic subunit called the human telomerase
reverse transcriptase (hTERT) [59]. The expression of hTR
subunit is expressed in all types of human cells and serves as a
template for telomere synthesis; however, hTERT is expressed
in cells with high telomerase activity, as tumor cells, but it
is not expressed in normal tissues [59–62]. Telomerase is
highly active in 90% of malignant tumors [63]. CRC patients
with increased levels of hTERT mRNA have been correlated
with tumor stage, histological grade, and significantly worse
survival than CRC patients with low hTERT levels [58, 64].
Higashi et al. [19] confirmed, using EGFP as reporter
gene, the high activity of the hTERT promoter in several
tumor cell lines of human esophageal cancer andmouse colon
adenocarcinoma, but they did not find activity in normal
human fibroblasts. The hTERT promoter has been used to
direct the therapeutic genes expression in cancer showing a
great tumor-specific capacity [62, 65–67].
Yang et al. [68] used an adenovirus based on the hTERT
promoter to deliver both apoptin gene and E1A gene into
CRC cells. This adenovirus induced 70–75% of cell growth
inhibition in CRC cells, showing 32.3% and 31.5% levels of
apoptosis and necrosis, respectively. Conversely, no effect
was observed in transfected human gastric epithelium. In
concordance with these results, the in vivo experiments with
mouse models of CRC proved that this adenovirus provoked
a slower tumor growth, increased the median survival time,
and reduced the number of metastatic lung nodules with
respect to the nontreated CRC mice. Higashi et al. [19]
utilized the hTERT promoter to direct in a specific way the
expression of two genes, interleukin-18 (IL-18) and TK, to
murine colorectal cancer cells. IL-18 is a proinflammatory
cytokine that activates the cytotoxicity of CD8+ T, CD4+ T,
and NK cells [69, 70]. The mentioned cells were sensitive to
ganciclovir and showed high levels of IL-18 secretion. These
cells were injected into mice in order to generate colorectal
cancer tumors in them. After treating them with ganciclovir,
thementioned tumors were totally eliminated, whereas in the
control groups the tumor growth was progressive. Besides,
a rise of CD8+ T and CD4+ T cells in the tumor zone was
observed, indicative of tumor-specific acquired immunity.
2.5. uPAR. Urokinase-type plasminogen activator receptor
(uPAR) gene codes a serine protease that catalyzes the trans-
formation of the inert zymogen plasminogen into plasmin
[20, 71]. uPAR gene is upregulated by the activated RAS
signaling pathway, the main signaling pathway activated in
colon cancer [72]. The components of the uPAR system are
overexpressed in diverse human tumors, such as pancreatic,
hepatic, breast, and especially gastrointestinal cancers [73–
76]. Tumor specific binding of activator protein (AP-1) to
uPAR promoter has been detected in ∼40% CRC patients,
and 39.8% of them showed this tumor specific binding in
the resected tumors in contrast to low or absent binding in
corresponding normalmucosa [76] demonstrating the tumor
specific activity of uPAR in CRC and not in normal tissue.
High uPAR protein levels have been correlated with poor
5-year survival in colon cancer patients [50] and increased
invasive capacity of tumor cells [77].
Teimoori-Toolabi et al. [78] proved the specific activity
of the uPAR promoter in colon and colorectal cancer cell
lines. Using the LacZ gene reporter under the control of the
uPAR promoter, they observed beta-gal expression in human
colorectal carcinoma (HTC116) and in colon cancer cells
(SW480), but not in normal colon cells and nontransformed
human umbilical vein endothelial cells. Afterward, they
used uPAR promoter to deliver TK gene in SW480 and
HCT116 cells. The growth of these cells with ganciclovir was
significantly decreased.
2.6. FGF18. Fibroblast growth factor 18 (FGF18) is a crucial
mitogen in embryonic limb development [79] with a sig-
nificant participation in the development of cartilage and
bone [80, 81]. Its overexpression has been associated to
different types of cancer, especially CRC [82, 83]. FGF18 is
downstreamofWnt pathways and is highly active in CRC [56,
82, 84]. In a study with 38 CRC and their respective normal
mucosa, 34 out of 38 CRC exhibited greater FGF18 mRNA
levels than the normalmucosa.Moreover, this overexpression
was associated with colon carcinogenesis from adenoma to
carcinoma [84], suggesting FGF18 as a novel marker for early
detection of colorectal tumors [82].
Teimoori-Toolabi et al. [85] researched the FGF18 pro-
moter activity in SW480, HCT116, human normal colon
cells, and umbilical vein endothelial cells. All cells were tran-
siently transfected with a plasmid with LacZ gene reported
under FGF18 promoter. Beta-gal staining showed a higher
expression in SW480 (5%) and HCT116 (10%) than in
human normal colon cells and umbilical vein endothelial
cells (0%). After demonstrating the tumor specific activity of
FGF18 promoter, this was used in a new plasmid to deliver
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TK gene to cancer cells. A significantly decreased growth
was shown in SW480 and HCT116 cells after ganciclovir
treatment.
2.7. KDR. The endothelial cell type-specific tyrosine kinase
domain-containing receptor (KDR) is a receptor for the
vascular endothelial growth factor (VEGF), playing an essen-
tial role in endothelial cell growth and development [86].
KDR expression has been detected in a variety of can-
cer cells and neogenetic vascular endothelial cells of the
neoplasm but has not been detected in normal cells [86–
89]. Currently, in a study with 110 CRC patients, single
nucleotide polymorphisms (SNP) of KDR were correlated
with microvessel density and overall survival [89]. Hansen et
al. [90] also linked SNP of KDR with a reduced recurrence
risk, this association being higher in CRC patients receiving
chemotherapy.
The specific activity of the KDR promoter to deliver both
TK and CD genes (KDR/CD-TK) in colon cancer cells has
been studied. CD/TK mRNA levels were detected in SW480
and SW620 cells (KDR positive human colon adenocarci-
noma) exhibiting both high sensibility to the prodrugs 5-FC
and ganciclovir. However, none of these results were observed
in LS174T cells (KDR negative human colon carcinoma) [91,
92].
3. Conclusions
Tissue-specific promoters are able to improve gene delivery
to tumor tissue, reducing at the same time the effect on
healthy tissues and increasing the efficacy against cancer
cells. Currently, a great amount of tumor-specific promoters
are known and several in vivo and in vitro assays have
revealed their specific activity in CRC, as well as their
potential use.However,more assayswill be needed in order to
demonstrate and enhance their efficacy. One possibility is the
use of enhancers, whose assays have proven to increase the
transcriptional activity of these promoters. The use of tissue-
specific promoters to deliver the expression of suicide genes
for the selective killing of tumors may be a novel strategy for
cancer treatment.
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